Tobias Levkovich

Being negative on pharmaceuticals and biotech has not been the right move thus far in 2015, but almost all the objective data suggests that underperformance is likely in the months ahead.

Tobias Levkovich

It's a little bit optimistic to believe that you can define the moves in stocks purely on the basis on stock buyback activity, it's too neat a package to tie up and tie a little bow around of and say 'perfect.' I wish it were that easy.

Tobias Levkovich